SlideShare une entreprise Scribd logo
1  sur  44
Raj Kiran Medapalli, MD, MPH. Nephrology Fellow May 19 th , 2009 Mount Sinai School of Medicine Division of Nephrology Journal Club
Pulse vs. Daily Oral Cyclophosphamide for Induction of Remission in ANCA-Associated Vasculitis The “CYCLOPS” Study European Vasculitis Study Group (EUVAS) Annals of Internal Medicine  19 May 2009   Journal Club by Raj Kiran Medapalli, MD
Outline ,[object Object],[object Object],[object Object],[object Object],[object Object]
Source: Brenner & Rector's The Kidney, 8 th  Edition.
Source: Jennette JC & Falk RJ. Small Vessel Vasculitis. NEJM. Nov 1997.  ,[object Object],[object Object],[object Object],[object Object],[object Object]
Source: Falk RJ & Jennette JC. JASN. 1997. C-ANCA, anti-Proteinase 3 P-ANCA, anti-Myeloperoxidase Anti-neutrophil cytoplasmic antibodies
Source: Xiao H, et al.  Am J of Path. Jan 2007.
 
Cyclophosphamide (Cyc) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Source: UpToDate
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Source: UpToDate
Hoffman GS et al. Annals of Int Med. March 1992. ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Hoffman GS et al. Annals of Int Med. March 1992.
Pulse Cyc in ANCA Vasculitis - EUVAS meta analysis  de Groot K et al. NDT 2001 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
CYC vs MTX for Induction - EUVAS RCT (NORAM) de Groot K et al. Arth & Rheum Aug 2005 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Adjunctive Plasma Exchange or High-Dosage Solumedrol for Severe Renal Vasculitis. EUVAS RCT (MEPEX)   Jayne DRW et al. JASN 2007 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Azathioprine for Maintainance Rx. (CYCAZAREM) Jayne D, et al. NEJM 2003. EUVAS RCT. ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
AZT vs. MTX for Maintenance Rx. FVSG RCT (WEGENT).   Pagnoux C, et al. NEJM 2008.  ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Pulse vs. Daily Oral Cyclophosphamide for Induction of Remission in ANCA-Associated Vasculitis The “CYCLOPS” Study European Vasculitis Study Group (EUVAS) Annals of Internal Medicine  19 May 2009
Study Design ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Intervention Pulse (IV or PO) Cytoxan Daily PO Cytoxan Induction 15 mg/kg IV Q2wkly x 3 doses 2 mg/kg/d, until remission 15 mg/kg IV or 5 mg/kg PO on 3 consecutive days, q3wkly, until remission (physician discretion) Initial maintenance Continue above for 3 months 1.5 mg/kg/d for 3 months Max dose 1.2 g per pulse 200 mg/d Age 60-70 Reduce by 2.5 mg/kg per pulse Reduce by 25%  Age >70 Reduce by 5 mg/kg per pulse Reduce by 50%  Creat 3.4 to 5.7 Reduce by 2.5 mg/kg per pulse - CBC checks Day 0,10,14 Q wkly x 1 month, Q2wkly x 1 month, then monthly 3 - 4 x 10 9 /L - Withhold dose and resume at a dose reduced by 25 mg/d when WBC > 4 x 10 9 /L 2 - 3 x 10 9 /L Reduce dose by 20% 1 - 2 x 10 9 /L Reduce dose by 40%
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Birmingham Vasculitis Activity Scores (BVAS) ,[object Object],[object Object],[object Object],[object Object]
Birmingham Vasculitis Activity Scores (BVAS) ,[object Object],[object Object]
 
 
 
 
Time to Remission ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Main Outcome Parameters by Treatment Group ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Main Outcome Parameters by Treatment Group ,[object Object],[object Object],[object Object],[object Object],[object Object]
Renal Outcomes ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Measures of disease activity ,[object Object],[object Object],[object Object],[object Object]
Cumulative dose ,[object Object],[object Object],[object Object],[object Object]
Adverse events ,[object Object],[object Object],[object Object],[object Object],[object Object]
Strengths of the study ,[object Object],[object Object],[object Object],[object Object],[object Object]
Weaknesses of the study ,[object Object],[object Object],[object Object],[object Object]
Conclusions ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Ongoing trials at EUVAS ,[object Object],[object Object],[object Object],[object Object],[object Object]
Summary of Rx options for induction ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Rx options for maintainance ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
EUVAS Guidelines
Thank You.

Contenu connexe

Tendances

Membranous Nephropathy (KDIGO 2021 Guidelines) - Dr. Gawad
Membranous Nephropathy (KDIGO 2021 Guidelines) - Dr. GawadMembranous Nephropathy (KDIGO 2021 Guidelines) - Dr. Gawad
Membranous Nephropathy (KDIGO 2021 Guidelines) - Dr. GawadNephroTube - Dr.Gawad
 
Managment of thrombocytopenia in ICU..pptx
Managment of thrombocytopenia in ICU..pptxManagment of thrombocytopenia in ICU..pptx
Managment of thrombocytopenia in ICU..pptxMarwa Besar
 
Polycythemai vera and Essential Thrombocytosis
Polycythemai vera and Essential ThrombocytosisPolycythemai vera and Essential Thrombocytosis
Polycythemai vera and Essential ThrombocytosisArtit Ungkanont
 
Renal transplantation in patients with lupus nephritis - prof. Ayman Refaie
Renal transplantation in patients with lupus nephritis - prof. Ayman Refaie Renal transplantation in patients with lupus nephritis - prof. Ayman Refaie
Renal transplantation in patients with lupus nephritis - prof. Ayman Refaie MNDU net
 
Renal Impairment in Multiple Myeloma
Renal Impairment in Multiple MyelomaRenal Impairment in Multiple Myeloma
Renal Impairment in Multiple MyelomaMohammed A Suwaid
 
Updates in management of membranous nephropathy - Dr. Mohammed Kamal Nassar
Updates in management of membranous nephropathy - Dr. Mohammed Kamal NassarUpdates in management of membranous nephropathy - Dr. Mohammed Kamal Nassar
Updates in management of membranous nephropathy - Dr. Mohammed Kamal NassarMNDU net
 
new oral anticoagulants
new oral anticoagulantsnew oral anticoagulants
new oral anticoagulantsderosaMSKCC
 
Transplantation associated Thrombotic microangiopathy (TA-TMA)
Transplantation associated Thrombotic microangiopathy (TA-TMA)Transplantation associated Thrombotic microangiopathy (TA-TMA)
Transplantation associated Thrombotic microangiopathy (TA-TMA)Jagjit Khosla
 
Approach to pancytopenia.pptx
Approach to pancytopenia.pptxApproach to pancytopenia.pptx
Approach to pancytopenia.pptxAnimesh Debbarma
 
Chronic myeloid leukemia dr. varun
Chronic  myeloid  leukemia  dr. varunChronic  myeloid  leukemia  dr. varun
Chronic myeloid leukemia dr. varunVarun Goel
 
Microangiopatias trombóticas (ptt suh) hematologia
Microangiopatias trombóticas (ptt suh) hematologiaMicroangiopatias trombóticas (ptt suh) hematologia
Microangiopatias trombóticas (ptt suh) hematologiaKitzia Abril
 
Paradigm hf journal club presentation
Paradigm hf journal club presentationParadigm hf journal club presentation
Paradigm hf journal club presentationGOPAL GHOSH
 
Newer Oral Anticoagulant in Chronic Kidney Disease
Newer Oral Anticoagulant in Chronic Kidney DiseaseNewer Oral Anticoagulant in Chronic Kidney Disease
Newer Oral Anticoagulant in Chronic Kidney DiseaseAbdullah Ansari
 
Approach to pancytopenia drbikal
Approach to pancytopenia drbikalApproach to pancytopenia drbikal
Approach to pancytopenia drbikalBikal Lamichhane
 
Antibody mediated rejection in kidney transplantation
Antibody mediated rejection in kidney transplantationAntibody mediated rejection in kidney transplantation
Antibody mediated rejection in kidney transplantationimrana tanvir
 
Lupus Nephritis (KDIGO 2021 Guidelines) - Dr. Gawad
Lupus Nephritis (KDIGO 2021 Guidelines) - Dr. GawadLupus Nephritis (KDIGO 2021 Guidelines) - Dr. Gawad
Lupus Nephritis (KDIGO 2021 Guidelines) - Dr. GawadNephroTube - Dr.Gawad
 

Tendances (20)

Membranous Nephropathy (KDIGO 2021 Guidelines) - Dr. Gawad
Membranous Nephropathy (KDIGO 2021 Guidelines) - Dr. GawadMembranous Nephropathy (KDIGO 2021 Guidelines) - Dr. Gawad
Membranous Nephropathy (KDIGO 2021 Guidelines) - Dr. Gawad
 
Managment of thrombocytopenia in ICU..pptx
Managment of thrombocytopenia in ICU..pptxManagment of thrombocytopenia in ICU..pptx
Managment of thrombocytopenia in ICU..pptx
 
Polycythemai vera and Essential Thrombocytosis
Polycythemai vera and Essential ThrombocytosisPolycythemai vera and Essential Thrombocytosis
Polycythemai vera and Essential Thrombocytosis
 
Renal transplantation in patients with lupus nephritis - prof. Ayman Refaie
Renal transplantation in patients with lupus nephritis - prof. Ayman Refaie Renal transplantation in patients with lupus nephritis - prof. Ayman Refaie
Renal transplantation in patients with lupus nephritis - prof. Ayman Refaie
 
Renal Impairment in Multiple Myeloma
Renal Impairment in Multiple MyelomaRenal Impairment in Multiple Myeloma
Renal Impairment in Multiple Myeloma
 
Updates in management of membranous nephropathy - Dr. Mohammed Kamal Nassar
Updates in management of membranous nephropathy - Dr. Mohammed Kamal NassarUpdates in management of membranous nephropathy - Dr. Mohammed Kamal Nassar
Updates in management of membranous nephropathy - Dr. Mohammed Kamal Nassar
 
new oral anticoagulants
new oral anticoagulantsnew oral anticoagulants
new oral anticoagulants
 
Cml1
Cml1Cml1
Cml1
 
HIV in Kidney Transplantation
HIV in Kidney TransplantationHIV in Kidney Transplantation
HIV in Kidney Transplantation
 
Transplantation associated Thrombotic microangiopathy (TA-TMA)
Transplantation associated Thrombotic microangiopathy (TA-TMA)Transplantation associated Thrombotic microangiopathy (TA-TMA)
Transplantation associated Thrombotic microangiopathy (TA-TMA)
 
Thrombotic microangiopathy
Thrombotic microangiopathyThrombotic microangiopathy
Thrombotic microangiopathy
 
Approach to pancytopenia.pptx
Approach to pancytopenia.pptxApproach to pancytopenia.pptx
Approach to pancytopenia.pptx
 
newer oral anticoagulents
newer oral anticoagulentsnewer oral anticoagulents
newer oral anticoagulents
 
Chronic myeloid leukemia dr. varun
Chronic  myeloid  leukemia  dr. varunChronic  myeloid  leukemia  dr. varun
Chronic myeloid leukemia dr. varun
 
Microangiopatias trombóticas (ptt suh) hematologia
Microangiopatias trombóticas (ptt suh) hematologiaMicroangiopatias trombóticas (ptt suh) hematologia
Microangiopatias trombóticas (ptt suh) hematologia
 
Paradigm hf journal club presentation
Paradigm hf journal club presentationParadigm hf journal club presentation
Paradigm hf journal club presentation
 
Newer Oral Anticoagulant in Chronic Kidney Disease
Newer Oral Anticoagulant in Chronic Kidney DiseaseNewer Oral Anticoagulant in Chronic Kidney Disease
Newer Oral Anticoagulant in Chronic Kidney Disease
 
Approach to pancytopenia drbikal
Approach to pancytopenia drbikalApproach to pancytopenia drbikal
Approach to pancytopenia drbikal
 
Antibody mediated rejection in kidney transplantation
Antibody mediated rejection in kidney transplantationAntibody mediated rejection in kidney transplantation
Antibody mediated rejection in kidney transplantation
 
Lupus Nephritis (KDIGO 2021 Guidelines) - Dr. Gawad
Lupus Nephritis (KDIGO 2021 Guidelines) - Dr. GawadLupus Nephritis (KDIGO 2021 Guidelines) - Dr. Gawad
Lupus Nephritis (KDIGO 2021 Guidelines) - Dr. Gawad
 

En vedette (12)

Rave ITN study
Rave ITN studyRave ITN study
Rave ITN study
 
9a1c wg mitchell-7-5-06
9a1c wg mitchell-7-5-069a1c wg mitchell-7-5-06
9a1c wg mitchell-7-5-06
 
Brief Review Of Chemotherapeutic Agents And Renal Failure
Brief Review Of Chemotherapeutic Agents And Renal FailureBrief Review Of Chemotherapeutic Agents And Renal Failure
Brief Review Of Chemotherapeutic Agents And Renal Failure
 
Pathogenesis of Glomerulonephritis
Pathogenesis of GlomerulonephritisPathogenesis of Glomerulonephritis
Pathogenesis of Glomerulonephritis
 
Cyclophosphamide ppt
Cyclophosphamide pptCyclophosphamide ppt
Cyclophosphamide ppt
 
Renal vasculitis
Renal vasculitisRenal vasculitis
Renal vasculitis
 
Systemic lupus erythematosus overview
Systemic lupus erythematosus   overviewSystemic lupus erythematosus   overview
Systemic lupus erythematosus overview
 
Cyclophosphamide
Cyclophosphamide Cyclophosphamide
Cyclophosphamide
 
Granulomatosis de wegener
Granulomatosis de wegenerGranulomatosis de wegener
Granulomatosis de wegener
 
Glomerulonefritis rapidamente progresiva (gnrp)
Glomerulonefritis rapidamente progresiva (gnrp)Glomerulonefritis rapidamente progresiva (gnrp)
Glomerulonefritis rapidamente progresiva (gnrp)
 
Glomerulonefritis rapidamente progresiva
Glomerulonefritis rapidamente progresivaGlomerulonefritis rapidamente progresiva
Glomerulonefritis rapidamente progresiva
 
cancer chemotherapy
cancer chemotherapycancer chemotherapy
cancer chemotherapy
 

Similaire à Pulse vs Daily Cyclophosphamide for ANCA Vasculitis Remission

Small cell lung cancer
Small cell lung cancerSmall cell lung cancer
Small cell lung cancerredho1
 
Chemotherapy in gliomas
Chemotherapy in gliomas Chemotherapy in gliomas
Chemotherapy in gliomas Dr Boaz Vincent
 
Cholangiocarcinoma
CholangiocarcinomaCholangiocarcinoma
Cholangiocarcinomaspa718
 
Philadephia chromosomal positive acute lymphoblastic leukemia
Philadephia chromosomal positive acute lymphoblastic leukemiaPhiladephia chromosomal positive acute lymphoblastic leukemia
Philadephia chromosomal positive acute lymphoblastic leukemiaspa718
 
m rcc optimal sequencing agents
m  rcc optimal sequencing agentsm  rcc optimal sequencing agents
m rcc optimal sequencing agentsmadurai
 
Ideal induction therapy for newly diagnosed AML. Do we have a consensus?
Ideal induction therapy for newly diagnosed AML. Do we have a consensus?Ideal induction therapy for newly diagnosed AML. Do we have a consensus?
Ideal induction therapy for newly diagnosed AML. Do we have a consensus?spa718
 
Multimodality Treatment Of Stage Iii Nsclc
Multimodality Treatment Of Stage Iii NsclcMultimodality Treatment Of Stage Iii Nsclc
Multimodality Treatment Of Stage Iii Nsclcfondas vakalis
 
Advances in cholangiocarcinoma
Advances in cholangiocarcinomaAdvances in cholangiocarcinoma
Advances in cholangiocarcinomaspa718
 
BP JCSO RCC Supplement_FINAL
BP JCSO RCC Supplement_FINALBP JCSO RCC Supplement_FINAL
BP JCSO RCC Supplement_FINALDean Celia
 
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...European School of Oncology
 
Medical Students 2011 - A. Cervantes - GASTROINTESTINAL CANCER - Pancreatic C...
Medical Students 2011 - A. Cervantes - GASTROINTESTINAL CANCER - Pancreatic C...Medical Students 2011 - A. Cervantes - GASTROINTESTINAL CANCER - Pancreatic C...
Medical Students 2011 - A. Cervantes - GASTROINTESTINAL CANCER - Pancreatic C...European School of Oncology
 
advanced stage ovary tumor.pptx
advanced stage ovary tumor.pptxadvanced stage ovary tumor.pptx
advanced stage ovary tumor.pptxDr. Sumit KUMAR
 
Chemotherapy in ca urinary bladder dr prasanta dash
Chemotherapy in ca urinary bladder dr prasanta dashChemotherapy in ca urinary bladder dr prasanta dash
Chemotherapy in ca urinary bladder dr prasanta dashPrasanta Dash
 
Small cell lung cancer staging and management
Small cell lung cancer staging and  managementSmall cell lung cancer staging and  management
Small cell lung cancer staging and managementSatyajitPradhanMPMMC
 
ANCA Associated Vasculitis - An Update 2014
ANCA Associated Vasculitis - An Update 2014ANCA Associated Vasculitis - An Update 2014
ANCA Associated Vasculitis - An Update 2014Richard McCrory
 
Adrenal ca dr.sharfuddin chowdhury
Adrenal ca dr.sharfuddin chowdhuryAdrenal ca dr.sharfuddin chowdhury
Adrenal ca dr.sharfuddin chowdhuryShakila Rifat
 
Adrenal ca dr.sharfuddin chowdhury
Adrenal ca dr.sharfuddin chowdhuryAdrenal ca dr.sharfuddin chowdhury
Adrenal ca dr.sharfuddin chowdhuryShakila Rifat
 
Adrenal ca dr.sharfuddin chowdhury
Adrenal ca dr.sharfuddin chowdhuryAdrenal ca dr.sharfuddin chowdhury
Adrenal ca dr.sharfuddin chowdhuryShakila Rifat
 

Similaire à Pulse vs Daily Cyclophosphamide for ANCA Vasculitis Remission (20)

Small cell lung cancer
Small cell lung cancerSmall cell lung cancer
Small cell lung cancer
 
Chemotherapy in gliomas
Chemotherapy in gliomas Chemotherapy in gliomas
Chemotherapy in gliomas
 
Cholangiocarcinoma
CholangiocarcinomaCholangiocarcinoma
Cholangiocarcinoma
 
Philadephia chromosomal positive acute lymphoblastic leukemia
Philadephia chromosomal positive acute lymphoblastic leukemiaPhiladephia chromosomal positive acute lymphoblastic leukemia
Philadephia chromosomal positive acute lymphoblastic leukemia
 
m rcc optimal sequencing agents
m  rcc optimal sequencing agentsm  rcc optimal sequencing agents
m rcc optimal sequencing agents
 
Ideal induction therapy for newly diagnosed AML. Do we have a consensus?
Ideal induction therapy for newly diagnosed AML. Do we have a consensus?Ideal induction therapy for newly diagnosed AML. Do we have a consensus?
Ideal induction therapy for newly diagnosed AML. Do we have a consensus?
 
Multimodality Treatment Of Stage Iii Nsclc
Multimodality Treatment Of Stage Iii NsclcMultimodality Treatment Of Stage Iii Nsclc
Multimodality Treatment Of Stage Iii Nsclc
 
Advances in cholangiocarcinoma
Advances in cholangiocarcinomaAdvances in cholangiocarcinoma
Advances in cholangiocarcinoma
 
BP JCSO RCC Supplement_FINAL
BP JCSO RCC Supplement_FINALBP JCSO RCC Supplement_FINAL
BP JCSO RCC Supplement_FINAL
 
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
 
Medical Students 2011 - A. Cervantes - GASTROINTESTINAL CANCER - Pancreatic C...
Medical Students 2011 - A. Cervantes - GASTROINTESTINAL CANCER - Pancreatic C...Medical Students 2011 - A. Cervantes - GASTROINTESTINAL CANCER - Pancreatic C...
Medical Students 2011 - A. Cervantes - GASTROINTESTINAL CANCER - Pancreatic C...
 
advanced stage ovary tumor.pptx
advanced stage ovary tumor.pptxadvanced stage ovary tumor.pptx
advanced stage ovary tumor.pptx
 
Leukemia - cancer
Leukemia - cancerLeukemia - cancer
Leukemia - cancer
 
Chemotherapy in ca urinary bladder dr prasanta dash
Chemotherapy in ca urinary bladder dr prasanta dashChemotherapy in ca urinary bladder dr prasanta dash
Chemotherapy in ca urinary bladder dr prasanta dash
 
Small cell lung cancer staging and management
Small cell lung cancer staging and  managementSmall cell lung cancer staging and  management
Small cell lung cancer staging and management
 
ANCA Associated Vasculitis - An Update 2014
ANCA Associated Vasculitis - An Update 2014ANCA Associated Vasculitis - An Update 2014
ANCA Associated Vasculitis - An Update 2014
 
H. Khaled - Bladder cancer - State of the art
H. Khaled - Bladder cancer - State of the artH. Khaled - Bladder cancer - State of the art
H. Khaled - Bladder cancer - State of the art
 
Adrenal ca dr.sharfuddin chowdhury
Adrenal ca dr.sharfuddin chowdhuryAdrenal ca dr.sharfuddin chowdhury
Adrenal ca dr.sharfuddin chowdhury
 
Adrenal ca dr.sharfuddin chowdhury
Adrenal ca dr.sharfuddin chowdhuryAdrenal ca dr.sharfuddin chowdhury
Adrenal ca dr.sharfuddin chowdhury
 
Adrenal ca dr.sharfuddin chowdhury
Adrenal ca dr.sharfuddin chowdhuryAdrenal ca dr.sharfuddin chowdhury
Adrenal ca dr.sharfuddin chowdhury
 

Dernier

Role of medicinal and aromatic plants in national economy PDF.pdf
Role of medicinal and aromatic plants in national economy PDF.pdfRole of medicinal and aromatic plants in national economy PDF.pdf
Role of medicinal and aromatic plants in national economy PDF.pdfDivya Kanojiya
 
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand UniversityCEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand UniversityHarshChauhan475104
 
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)MohamadAlhes
 
Giftedness: Understanding Everyday Neurobiology for Self-Knowledge
Giftedness: Understanding Everyday Neurobiology for Self-KnowledgeGiftedness: Understanding Everyday Neurobiology for Self-Knowledge
Giftedness: Understanding Everyday Neurobiology for Self-Knowledgeassessoriafabianodea
 
Apiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptApiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptkedirjemalharun
 
Primary headache and facial pain. (2024)
Primary headache and facial pain. (2024)Primary headache and facial pain. (2024)
Primary headache and facial pain. (2024)Mohamed Rizk Khodair
 
Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.Prerana Jadhav
 
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners
 
Culture and Health Disorders Social change.pptx
Culture and Health Disorders Social change.pptxCulture and Health Disorders Social change.pptx
Culture and Health Disorders Social change.pptxDr. Dheeraj Kumar
 
Introduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiIntroduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiGoogle
 
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptxPresentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptxpdamico1
 
Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.ANJALI
 
Valproic Acid. (VPA). Antiseizure medication
Valproic Acid.  (VPA). Antiseizure medicationValproic Acid.  (VPA). Antiseizure medication
Valproic Acid. (VPA). Antiseizure medicationMohamadAlhes
 
Basic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfBasic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfDivya Kanojiya
 
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
COVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptxCOVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptx
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptxBibekananda shah
 
Phytochemical Investigation of Drugs PDF.pdf
Phytochemical Investigation of Drugs PDF.pdfPhytochemical Investigation of Drugs PDF.pdf
Phytochemical Investigation of Drugs PDF.pdfDivya Kanojiya
 
HERBS AS HEALTH FOOD - Brief introduction and therapeutic applications of: N...
HERBS AS HEALTH FOOD - Brief introduction and therapeutic applications of:  N...HERBS AS HEALTH FOOD - Brief introduction and therapeutic applications of:  N...
HERBS AS HEALTH FOOD - Brief introduction and therapeutic applications of: N...Divya Kanojiya
 
Presentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPresentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPrerana Jadhav
 
History and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfHistory and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfSasikiranMarri
 
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
PNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdfPNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdf
PNEUMOTHORAX AND ITS MANAGEMENTS.pdfDolisha Warbi
 

Dernier (20)

Role of medicinal and aromatic plants in national economy PDF.pdf
Role of medicinal and aromatic plants in national economy PDF.pdfRole of medicinal and aromatic plants in national economy PDF.pdf
Role of medicinal and aromatic plants in national economy PDF.pdf
 
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand UniversityCEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
 
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)
 
Giftedness: Understanding Everyday Neurobiology for Self-Knowledge
Giftedness: Understanding Everyday Neurobiology for Self-KnowledgeGiftedness: Understanding Everyday Neurobiology for Self-Knowledge
Giftedness: Understanding Everyday Neurobiology for Self-Knowledge
 
Apiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptApiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.ppt
 
Primary headache and facial pain. (2024)
Primary headache and facial pain. (2024)Primary headache and facial pain. (2024)
Primary headache and facial pain. (2024)
 
Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.
 
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
 
Culture and Health Disorders Social change.pptx
Culture and Health Disorders Social change.pptxCulture and Health Disorders Social change.pptx
Culture and Health Disorders Social change.pptx
 
Introduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiIntroduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali Rai
 
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptxPresentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
 
Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.
 
Valproic Acid. (VPA). Antiseizure medication
Valproic Acid.  (VPA). Antiseizure medicationValproic Acid.  (VPA). Antiseizure medication
Valproic Acid. (VPA). Antiseizure medication
 
Basic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfBasic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdf
 
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
COVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptxCOVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptx
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
 
Phytochemical Investigation of Drugs PDF.pdf
Phytochemical Investigation of Drugs PDF.pdfPhytochemical Investigation of Drugs PDF.pdf
Phytochemical Investigation of Drugs PDF.pdf
 
HERBS AS HEALTH FOOD - Brief introduction and therapeutic applications of: N...
HERBS AS HEALTH FOOD - Brief introduction and therapeutic applications of:  N...HERBS AS HEALTH FOOD - Brief introduction and therapeutic applications of:  N...
HERBS AS HEALTH FOOD - Brief introduction and therapeutic applications of: N...
 
Presentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPresentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous System
 
History and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfHistory and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdf
 
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
PNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdfPNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdf
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
 

Pulse vs Daily Cyclophosphamide for ANCA Vasculitis Remission

  • 1. Raj Kiran Medapalli, MD, MPH. Nephrology Fellow May 19 th , 2009 Mount Sinai School of Medicine Division of Nephrology Journal Club
  • 2. Pulse vs. Daily Oral Cyclophosphamide for Induction of Remission in ANCA-Associated Vasculitis The “CYCLOPS” Study European Vasculitis Study Group (EUVAS) Annals of Internal Medicine 19 May 2009 Journal Club by Raj Kiran Medapalli, MD
  • 3.
  • 4. Source: Brenner & Rector's The Kidney, 8 th Edition.
  • 5.
  • 6. Source: Falk RJ & Jennette JC. JASN. 1997. C-ANCA, anti-Proteinase 3 P-ANCA, anti-Myeloperoxidase Anti-neutrophil cytoplasmic antibodies
  • 7. Source: Xiao H, et al. Am J of Path. Jan 2007.
  • 8.  
  • 9.
  • 10.
  • 11.
  • 12.
  • 13.
  • 14.
  • 15.
  • 16.
  • 17.
  • 18. Pulse vs. Daily Oral Cyclophosphamide for Induction of Remission in ANCA-Associated Vasculitis The “CYCLOPS” Study European Vasculitis Study Group (EUVAS) Annals of Internal Medicine 19 May 2009
  • 19.
  • 20. Intervention Pulse (IV or PO) Cytoxan Daily PO Cytoxan Induction 15 mg/kg IV Q2wkly x 3 doses 2 mg/kg/d, until remission 15 mg/kg IV or 5 mg/kg PO on 3 consecutive days, q3wkly, until remission (physician discretion) Initial maintenance Continue above for 3 months 1.5 mg/kg/d for 3 months Max dose 1.2 g per pulse 200 mg/d Age 60-70 Reduce by 2.5 mg/kg per pulse Reduce by 25% Age >70 Reduce by 5 mg/kg per pulse Reduce by 50% Creat 3.4 to 5.7 Reduce by 2.5 mg/kg per pulse - CBC checks Day 0,10,14 Q wkly x 1 month, Q2wkly x 1 month, then monthly 3 - 4 x 10 9 /L - Withhold dose and resume at a dose reduced by 25 mg/d when WBC > 4 x 10 9 /L 2 - 3 x 10 9 /L Reduce dose by 20% 1 - 2 x 10 9 /L Reduce dose by 40%
  • 21.
  • 22.
  • 23.
  • 24.
  • 25.  
  • 26.  
  • 27.  
  • 28.  
  • 29.
  • 30.
  • 31.
  • 32.
  • 33.
  • 34.
  • 35.
  • 36.
  • 37.
  • 38.
  • 39.
  • 40.
  • 41.
  • 42.